Many Src Homology 3 (SH3) domains function as molecular adhesives in intracellular signal transduction. Based on previous ultrastructural studies, short motifs which bind to the ®rst SH3 domains of the adapters Crk and CRKL were selectively mutagenised to generate Crk/ CRKL SH3-binding peptides of very high anity and selectivity. Anities were increased up to 20-fold compared to the best wildtype sequences, while the selectivity against a similar SH3 domain [Grb2SH3(N)] was not only retained, but sometimes increased. Blot techniques with GST-fusion peptides and in solution precipitation assays with biotinylated high anity Crk binding peptides (HACBPs) were subsequently used to analyse the binding of these sequences to a large panel of SH3 domain-containing fusion proteins. Only those proteins which contained the CrkSH3(1) or CRKLSH3(1) domains bound eciently to the HACBPs. A GST-HACBP fusion protein precipitated Crk and CRKL proteins out of 35 S-labelled and unlabelled cell lysates. Very little binding of other cellular proteins to HACBP was detectable, indicative of a great preference for Crk and CRKL when compared to the wide variety of other endogenous cellular proteins. Moreover, HACBP disrupted in vitro preexisting Crk-complexes with DOCK180 and the exchange factors SoS and C3G, which are known targets of Crk adapters, in a concentration dependent manner. HACBP-based molecules should therefore be useful as highly selective inhibitors of intracellular signalling processes involving Crk and CRKL.
Introduction
Src homology (SH) 2 and SH3 domains are modular structures of many proteins and are often involved in intracellular signalling events. SH2 domains usually bind to speci®c tyrosine-phosphorylated epitopes of proteins and many SH3 domains were shown to complex with amino acid motifs which are structurally similar to type II poly-proline-helices (Williamson, 1994; Feller et al., 1994b; Pawson, 1995) . Additionally, basic amino acids can strongly contribute to the anity and speci®city of binding to SH3 domains of proteins like Crk and Grb2 (Knudsen et al., 1994 Sparks et al., 1996) . In some of the SH3-binding sequences, the crucial basic residues are located at the C-terminus of the interacting sequence, resulting in the consensus motif PxxPxK/R (class II-peptides) (Feng et al., 1994; Sparks et al., 1996) . On the other hand, class I-binding sites often contain basic residues in front of a proline-rich stretch (Feng et al., 1994; Sparks et al., 1996; Cheng et al., 1994; Weng et al., 1995) . Some SH3 domains, including the SrcSH3 and Grb2SH3(N) domains, are able to bind peptides of both classes (Feng et al., 1994; Sparks et al., 1996) . SH2 and SH3 domains are not only found as accessory protein interaction domains in various enzymes and structural proteins, they are also utilised as virtually exclusive building blocks of a class of signalling proteins known as the SH2/SH3 adapter family. One member of this protein family, c-Crk II, is composed of an N-terminal SH2 domain, followed by two SH3 domains (Reichman et al., 1992; Matsuda et al., 1992) . The SH3 domains are separated by a`spacer region' which contains a protein conformation-regulating tyrosine residue (Feller et al., 1994a; Rosen et al., 1995) . c-Crk II and Crk-like (CRKL, a homologous but distinct gene product abundant in some hematopoietic cell lines) are substrates for tyrosine kinases, including those of the Abl family (c-Abl, Bcr-Abl and Arg) (Ren et al., 1994; Feller et al., 1994a; ten Hoeve et al., 1994; Wang et al., 1996b) . Although detailed ultrastructural data are missing at this point, indirect evidence suggests that a CrkSH2-Y221 interaction somehow inhibits binding of the ®rst CrkSH3 domain to other cellular signalling proteins (Feller et al., 1994a) . The functional consequences of CRKL phosphorylation at a homologous site (Y207) in Bcr ± Abl-positive hematopoietic cells (de Jong et al., 1997) are currently not understood.
The analysis of CrkSH2 as well as SH3 binding to other cellular proteins has not only been important in de®ning the ultrastructural features of Src homology domain interactions but has also pointed to putative intracellular signalling functions. Recent evidence exists for a role of Crk family proteins in a number of cellular signalling pathways, including T-and B-cell receptor signalling (Buday et al., 1996; Reedquist et al., 1996; Ingham et al., 1996) , Integrin-mediated interactions of extracellular matrix components with intracellular signal transduction pathways (Vuori et al., 1996) , the NGF-induced dierentiation of PC12 pheochromocytoma cells (Teng et al., 1995; Torres and Bogenmann, 1996) and apoptosis in Xenopus oocytes (Evans et al., 1997) . In addition, CRKL appears to play an important role in the manifestation of Bcr-Abl positive human leukemias (ten Hoeve et al., 1994; Sattler et al., 1996; Senechal et al., 1996) .
The protein binding speci®cities of the ®rst SH3 domains of Crk and CRKL are known to be similar (Feller et al., 1995b) . Crk/CRKLSH3(1)-binding proteins currently identi®ed include the tyrosine kinases cAbl, Bcr ± Abl and Arg, the guanine nucleotide exchange factors C3G and SoS (Feller et al., 1994a,b; Knudsen et al., 1994; Tanaka et al., 1994; ten Hoeve et al., 1994; Wang et al., 1996b) as well as the possibly non-enzymatic proteins Eps15 and DOCK180 (Schumacher et al., 1995; Hasegawa et al., 1996) . No speci®c protein interactions have been reported at this point for the C-terminal SH3 domains of Crk and CRKL, despite attempts of various laboratories to ®nd interacting partners or motifs.
The determinants of CrkSH3(1) binding to peptides have been elucidated in some detail using C3G-and SoSderived sequences Wu et al., 1995) . C3G, a guanine-nucleotide exchange factor for the GTPases Rap 1 A and B (Gotoh et al., 1995) , contains four potential CrkSH3 binding motifs (CB1 to CB4) clustered in the central region of the protein (Knudsen et al., 1994; Tanaka et al., 1994) . A 10-amino acid peptide corresponding to the CB1-motif was found to bind the CrkSH3(1) domain with a K d of 1.9 mM , a remarkably high anity when compared to other SH3-interacting peptides of this length measured with tryptophan¯uorescence (Lee et al., 1995) . A conserved lysine residue present in all C3G-CB motifs (consensus P-P-x-L-P-x-K) contributes greatly to the peptide and protein binding speci®city of the CrkSH3(1) domain. Peptide mutagenesis revealed a more than eightfold drop in anity for CrkSH3(1) when this lysine was replaced by an arginine. At the same time, binding of the (K?R)-mutant peptide to the Grb2SH3(N) domain was greatly increased. These results were con®rmed and explained by ultrastructural data, which showed that the lysine is tightly bound in a uniquely structured pocket largely formed by an SH3 region named the`RT-loop' (Wu et al., 1995) .
Since highly selective CrkSH3(1) binding peptides with very high anity could be useful as speci®c inhibitors to study the signalling of Crk family proteins, we decided to perform a mutagenesis study based on the sequences of naturally occurring CrkSH3(1) binding motifs, as well as the available ultrastructural information of SH3 domain-peptide interactions (Wu et al., 1995) . The resulting high anity CrkSH3(1) binding peptides (HACBPs) have a K d of up to 100 nM to CrkSH3(1), while exhibiting an approximately 100-fold weaker interaction with the Grb2SH3(N) domain. Subsequent precipitation assays and Far Western blots with 34 dierent SH3 domains and studies with cellular proteins demonstrated that the HACBP interactions are highly speci®c for Crk and CRKL. Finally, HACBPs were able to disrupt in vitro complexes between the CrkSH3(1) domain and its known targets DOCK180, SoS and, in part, C3G.
Results
Increased peptide anity and selectivity through mutagenesis of the C3G-derived CB-1 sequence
The binding of C3G to Crk proteins is mediated by four CrkSH3 binding (CB) motifs (Knudsen et al., 1994) . Previous experiments identi®ed a ten amino acid peptide (CB-1) which binds to CrkSH3(1) with a K d of 1.9 mM. An alanine scan through this C3G-CB-1 peptide demonstrated that the residues P 284 , L 286 , P 287 and K 289 are particularly important for the binding anity towards the CrkSH3(1) domain. The lysine residue was shown to contribute strongly to the almost unique SH3 binding speci®city of CB-1 Wu et al., 1995) . Replacement of K 289 by an arginine reduces the anity of the CB-1 peptide approximately eightfold (to 17.2 mM) and signi®cantly aects the interactions observed in the crystallised peptide-SH3 complex (Wu et al., 1995) . The stronger binding of a SoS1-related peptide (PPPVPPRRRR; 5.2 mM) which does not contain a lysine but an arginine in the corresponding position was therefore surprising. This result prompted us to speculate that the binding of the C3G-CB1 to CrkSH3(1) might be a suboptimal ®t, and that other amino acids in the SoS1-related peptide interact more strongly with the CrkSH3(1) domain than the equivalent positions in CB-1. Thus, it might be possible to generate peptides with very high binding anity by making chimeric mutant peptides with features from C3G and SoS1-related sequences. In an initial round of mutagenesis, a number of basic parameters was tested and the binding of the mutant peptides analysed by a competition assay previously described . In this assay a GST-CB1 fusion peptide is used to precipitate c-Crk from cellular protein extracts. Crk binding to immobilised GST-CB-1 can be competed by the addition of soluble CrkSH3(1) binding peptides, permitting a quick estimate of binding anities for a panel of mutant peptides (Figure 1 ). Simple reversion of the CB-1 motif or replacement of L-by D-amino acids abolished the capacity of the CB-1 sequence to compete eciently with the binding of GST-CB-1. However, amidation of the C-terminal residue in the wildtype CB-1 peptide, which eliminates the negative C-terminal charge following the cluster of positively charged amino acids, lead to a signi®cantly better activity in the competition assay and a threefold better binding as determined by tryptophan¯uorescence. In addition, the exchange of K 290 , which follows the speci®city-determining K
289
, to arginine leads to another almost twofold increase in peptide anity. On the other hand, elimination of the terminal residues, as well as mutation of L 286 to proline or valine diminished peptide binding to the CrkSH3(1) domain (Figures 1  and 2) . In a subsequent round of peptide mutagenesis, we attempted to improve the anity even further, while eliminating unnecessary residues and retaining the great binding speci®city of the wildtype sequence. Extension of the C-terminus with another arginine increased the K d further to approximately 100 nM ( Figure 2 ). This arginine is not present in CB-1 but is contained in the SoS1-related peptide mentioned above. Mutation of A 285 to proline resulted also in a slight increase of the SH3-binding anity in several peptides tested (Figures 1 and 2 ). It is noteworthy that the mutagenesis improved binding for both, CrkSH3(1) and Grb2SH3(N), often to a similar degree. Thus the preference of mutant peptides which contain the speci®city-determining K 289 for the CrkSH3(1) domain was often fully retained and sometimes even increased, up to a more than 180-fold selectivity for the CrkSH3(1) domain over the Grb2SH3(N) domain.
D-amino acid peptides and class I-peptides bind very poorly to the Crk SH3(1) domain It has been previously suggested that class-I SH3 binding peptides with signi®cant anity may be generated for SH3 domains, when class-II binding peptides for an SH3 domain are known and single con®rmatory cases were published (Feng et al., 1994; Lim et al., 1994) . In order to investigate whether this is true for the CrkSH3(1) domain, we tested a variety of peptides with positively charged residues preceding the proline-rich sequence stretch. However, all of the tested peptides bound very poorly or not at all to CrkSH3(1). Interestingly, some of these peptides bound with considerable anity to the Grb2SH3(N) domain, which is in agreement with recent results from phage display screens that also demonstrated the binding of class-I peptides to GrbSH3(N) (Sparks et al., 1996) . Furthermore, the corresponding D-amino acid peptides were tested for binding to CrkSH3(1). One of the Dpeptides showed detectable binding even though it was very poor. Similar to these results, the identi®cation of low anity D-amino acid binding peptides for the Src SH3 domain by mirror image phage display has been reported previously (Schumacher et al., 1996) .
Far Western blot on SH3 domains with GST-HACBP-1 SH3 binding peptides with very high anity could potentially be useful as speci®c inhibitors of intracellular signal transduction, but only if they do not bind to a large number of SH3-containing proteins with similar anity. Therefore, the SH3 binding selectivity of the two best CrkSH3(1) binding peptides was further analysed. First, Far Western blot assays were performed as previously described Feller et al., 1995b) to determine the binding of the GST-fusion peptide C3G282-292(K290R, Q292R) [designated HACBP-1(AL)] to various SH3 domains. A wide variety of anity-puri®ed SH3 domaincontaining GST-fusion proteins was tested in this assay, together with some control proteins (GST-tag alone, GST-SH2s).
35
S-labelled, anity-puri®ed GST-HACBP-1(AL) (GST-PPPALPPKRRR) was used as a probe. As expected, the protein probe detected eciently proteins containing the cellular CrkSH3(1) or CRKLSH3(1) domains (Figure 3) . A clearly weaker signal is seen with the GST-v-CrkSH2SH3 protein, consistent with a 14-fold lower K d of C3G-CB-1 for this protein and explained through a mutation of the CT10-virus sequence in a c-Crk Figure 1 Binding properties of mutated CrkSH3 binding peptides. Peptides derived by mutagenesis of the wildtype C3G Crkbinding motif-1 (C3G CB-1) were tested in a competition assay for their capacity to block c-Crk II precipitation from c-Crk overexpresssing CEF lysates with GST-CB-1 peptide as previously described . Precipitated c-Crk II is visualised by Western blot. The anity (K d +s.d.) of peptides which competed eciently in the precipitation assay was determined by tryptophan¯uorescence. The eects of C-terminal amidation (CONH 2 ) as well as D-amino acid peptides (D), reverted peptides (reverse), amino acid exchanges and truncations were tested. Anities marked with an asterisk were already published . and are included for comparison. The corresponding amino acid positions in the C3G-Protein are also indicated crucial residue involved in speci®c peptide binding. In contrast, none of the other SH3 domains tested showed a signal beyond background. While the blot assay allows a fast screening of many domains for high anity binding, low anity interactions are not easily detectable with this assay, since the GST protein itself dimerises with low anity (Maru et al., 1996) . This results in a weak, but detectable background from the GST-interaction in long exposures, masking other weak signals. To also detect lower anity interactions and to maintain the full structural integrity of the SH3 domains, a precipitation assay with biotinylated HACBP-peptides was developed.
In solution precipitation of SH3 domains
In this assay, biotinylated HACBPs are immobilised on streptavidin-agarose beads. Peptide-binding SH3 do- . High anity peptides marked with double asterisk were measured using a stock solution of 0.25 mg/ml instead of 5 mg/ml. In the measurement marked with a cross, the DF was very small, resulting in low accuracy. NB: No detectable binding
Figure 3 Far Western blot of a GST-SH3 domain panel with radiolabeled GST-HACBP1. 1 mg of GST or equimolar amounts of puri®ed GST-fusion proteins were separated by PAGE, membrane-immobilised and renaturated overnight. The Crk proteins are derived from mouse c-crk II, human crkl sequences and CT10-viral v-crk DNA. GST-HACBP-1(AL) was radiolabelled, anity puri®ed and used as a probe at 0.5 mg/ml. The blots were then exposed to X-ray ®lm (Figure 4 , middle and lower panels). This peptide was chosen, because its nonbiotinylated counterpart exhibited the highest selectivity for Crk of the identi®ed HACBPs, as determined by tryptophan uorescence (Figure 2 ). Bio-1(AL) precipitated only such fusion proteins eciently which contain the Nterminal SH3 domains of Crk or CRKL. Again, the amount of precipitated fusion protein is considerably lower in case of v-Crk, further demonstrating reduced binding of the CT10 virus-derived v-CrkSH3 domain. Most of the other SH3-fusion proteins were not precipitated in Coomassie-detectable amounts. However, a few of the fusion proteins, namely the SH3 domains of Fyn, Lyn and Hck were precipitated in small amounts. Since it was previously published that the SH3 domains of Fyn, Lyn and Hck can bind lysine-containing class I-peptides (Cheng et al., 1994) , a lysine-dependent binding with a reverted peptide orientation seemed possible. Finally, this was excluded by the ®nding that the negative control peptide Bio-3(K?L) also bound to these domains (data not shown), indicating nonspeci®c binding to Pro-rich peptides.
Precipitation of endogenous cellular proteins with GST-HACBP
To test whether the selectivity of the HACPBs observed in vitro also applies for endogenous cellular proteins, GST-HACBP-1(AL) was analysed for binding of cellular proteins extracted from three dierent cell lines. (Figure 7 ). These proteins have been previously identi®ed as DOCK180, SoS and C3G (Feller et al., 1995b; Hasegawa et al., 1996) . Although the amount of precipitated p155/p145 was clearly reduced by competition with increased HACBPconcentrations, the binding was, in contrast to p185 and p170, not totally abolished (Figure 7b ). Similar results were obtained with PC12 lysates (data not shown). This suggests that C3G binds somewhat stronger to the CrkSH3(1) domain than SoS or DOCK180, probably because of its four binding motifs which precisely match the CrkSH3(1) binding consensus.
Discussion
The rationally developed CrkSH3 binding peptides presented here do not only exhibit a very high anity and selectivity, but are also able to block and disrupt Crk mediated protein-protein interactions in vitro. For determining the molecular basis of the interaction, the crystal structure analysis of the CrkSH3(1)-CB-1-complex had been very useful in the past since it unraveled the speci®city determinants of the CrkSH3(1) domain (Wu et al., 1995) . Therefore, the CrkSH3(1) domain was again co-crystallised with the HACBPs (AL-and PL-type) to possibly detect novel or signi®cantly changed interactions between the HACBPs and the CrkSH3(1) domain when compared to those of the CB-1 (wildtype) peptide sequence. However, we were unable to ®nd prominent additional interactions or changes in amino acid contacts when comparing the electron density maps of crystals with CB-1 or the HACBPs, respectively (I Moare®, B Fehlhaber, SF and J Kuriyan; unpublished data). Consistent with this result, the data of the selective peptide mutagenesis (Figures 1 and 2 ) also suggest that multiple subtle improvements underly the nearly 20-fold better binding of the HACBPs compared to the wildtype CB-1 sequence. It seems therefore unlikely that, with the current technology, a computational I P I P I P I P I P I P I P I P I P I P
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14 -* q I P I P I P I P I P I P I P I P I P I P I P Nck SH3 (1) Nck SH3 (2) Nck SH3 ( Our results suggest that a continuation of the chimeric peptide mutagenesis of naturally occurring binding sequences described here might be a successful strategy to further improve the HACBP anity. The ongoing identi®cation of novel Crk and CRKLSH3-binding proteins (Schumacher et al., 1995 , Hasegawa et al., 1996 Matsuda et al., 1996) continues to yield candidate sequences for further testing. One advantage of further testing of endogenous Crk/CRKLSH3 binding sequences, instead of designing or selecting novel ones, should be the minimisation of toxic eects in cells, since in vivo selection pressure has likely already eliminated sequences not compatible with important intracellular processes. It is foreseeable that the extension of a poly-proline motif or a basic amino acid cluster beyond a certain length will start to functionally interfere with other cellular processes involving protein-protein interactions, like nuclear protein import and pro®lin-binding. In addition, many functional protein motifs involved in intracellular signals are probably still unknown. Therefore, bacterial proteins and ovalbumin to minimise nonspeci®c binding. Precipitated proteins were separated by 12% SDS ± PAGE and Coomassie stained. For comparison, 5 mg of the input proteins are shown. The closed circle indicates an E. coli protein which binds nonspeci®cally. Middle and lower panels: precipitation experiments with Bio-1(AL), a panel of GST-SH3 fusion proteins and some control proteins. Experimental setup was as before, except that BSA instead of ovalbumin was used for supplementation. 5 mg of input proteins (I) are included on the gel next to the corresponding precipitates (P). The asterisk indicates nonspeci®cally precipitated BSA 14 the frequent evaluation of novel chimeric sequences for unwanted cytotoxicity seems an essential companion of the mutagenesis, especially when non-natural sequences are included.
Truly speci®c inhibitors of signal transduction pathways will be important tools in basic research and could be useful for therapeutic purposes, including cancer therapy. The general requirements for eective pharmacological agents with low toxicity are an ecient targeting to the appropriate cells or tissues, as well as sucient anity, selectivity and stability. The developed HACBPs meet at least some of these requirements. Their anity is clearly one of the highest published for SH3-peptide complexes. For a`consolidated ligand', a peptide which binds simultaneously to the SH2 and SH3 domains of the Abl kinase protein, an anity of approximately 250 nM was measured . The anity of the HIV Nef protein to the HckSH3 domain, determined by surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), is also similar (Lee et al., 1995) but the corresponding Nef-peptide bound with a K d of 91 mM (measured by Trp-¯uorescence).
The roles of Crk family proteins are currently analysed in many dierent cellular systems. There are indications for their potential involvement in Trkreceptor signalling leading to dierentiation of PC12 cells (Teng et al., 1995, Torres and Bogenmann, 1995) . Other results document that Crk and CRKL form signalling complexes after T-and B-cell receptor stimulation (Buday et al., 1996; Reedquist et al., 1996; Ingham et al., 1996) or suggest a role for Crk in Integrin-mediated signal transduction (Vuori et al., 1996) . Moreover, the CRKL protein has been shown to form complexes with Bcr ± Abl, the fusion protein found in the majority of chronic myelogenous leukaemias (ten Hoeve et al., 1994; Sattler et al., 1996) . The deletion of the CRKL binding site in Bcr ± Abl or delivery of CRKL-speci®c antisense RNA leads to a partial reduction of the transforming potential of Bcr ± Abl (Senechal et al., 1996; Tari et al., 1997) . Since the HACBPs are able to disrupt protein complexes in vitro, they are currently tested in cells for biological activity. Blocking of Crk-and CRKL-speci®c pathways with HACBPs will give insight into the roles of Crk family proteins in various cell types.
Materials and methods
Peptide synthesis
The Crk binding peptides were synthesised by the Fmoc (¯uorenylmethoxycarbonyl) / t-butyl based solid phase peptide chemistry method on an ABI 431A (Perkin Elmer) peptide synthesizer. The biotinylated peptides were also synthesised by Fmoc methodology. However, upon removal of the ®nal N-terminal Fmoc, the peptide was biotinylated with four equivalents of NHS-LC-Biotin II (succinimidyl-6-(biotinamido)hexanoate) (Pierce), 100 ml DIEA (diisopropylethylamine) in 10 ml DMF (dimethylformamide) for 4 h. The biotinylated peptides were then deprotected and cleaved. All crude peptides were puri®ed by reverse-phase HPLC on a preparative (2.5625 cm) Vydac C 4 column with linear gradients of 99.95% acetonitrile plus 0.05% TFA versus 0.1% aqueous TFA. Mass spectra for synthetic peptides were obtained on a Sciex API (Perkin Elmer) single quadropole mass spectrometer. Samples were introduced via HPLC by a Michrom Bioresources ultrafast microprotein analyser through a Zorbax C 8 5 mm, 300 A Ê pore size, 0.36150 mm column. An isocratic gradient of 70% B, with a¯ow rate of 50 ml/ min was employed (solvent A=2% ACN, 0.1% TFA in H 2 O, solvent B=10% H 2 O, 0.09% TFA in ACN). All mass spectral samples were fractions of preparative HPLC and were dissolved in approx. 35% ACN, 65% H 2 O. Amino acid analysis were performed on a ABI 420A hydrolyser/derivatiser with a 130A separation system (Perkin Elmer Corp.). The peptides were hydrolysed using 6N HCl at 2008C for 30 min and then derivatised as the PTC (phenylisothiocyanate) derivative. The amino acid mixture was then separated by HPLC on a Brownlee PTC C 18 , 5 mm pore size, 2.16220 mm with a linear gradient of 70% acetonitrile versus water. Both solvents were buered with sodium acetate to pH 5.4. The amino acid determination were quantitated by comparison of the unknown peak ratios with an equimolar amino acid standard. 
Expression of GST-fusion proteins
Two oligonucleotides encoding the high anity CrkSH3 binding peptide (PPPALPPKRRR-stop) were synthesised, hybridised and cloned into the BamHI-site of the GSTexpression vector pGEX-2T, resulting in the GST-High Anity CrkSH3-Binding Peptide (HACBP)-1(AL) construct. The insert was analysed by dideoxy-sequencing. Many GST-SH3 fusion constructs were described previously (Feller et al., 1994a,b; Knudsen et al., 1994 Knudsen et al., , 1995 Cheng et al., 1994; Wang et al., 1996a) The mouse c-Crk II in pBlueSK ( gift of Hisamaru Hirai, University of Tokyo, Japan) was ampli®ed by PCR using the following forward primer: GGGGGAT CCCT GGTTCCTCGCAT GGC GGGCAACTTCGACTCG and a reverse primer that included the unique EcoRI site within the Crk SH2 domain. The PCR-ampli®ed fragment was then cloned into the BamHI and EcoRI sites of the pGEX-KN vector (Hakes and Dixon, 1992) and fully sequenced. The full length construct was then generated by the insertion of the murine Crk 3' portion from the EcoRI site to the 3' end. To construct GST-NckSH3(1), the following primers were used to amplify a human Nck fragment from amino acid 1 ± 56 by PCR: GCGGGATC-CATGGCAGAAGTGGTA and GCGGA ATTCTTACAC ATAGTTAGAAGGCACAAAACC. The fragment was cloned into BamHI ± EcoRI digested pBluescript. After con®rming the sequence, it was subloned into BamHI ± EcoRI digested pGEX4T-1.
GST-fusion protein expression was usually induced at 258C for 2 h through the addition of 0.1 mM IPTG. In cases of signi®cant degradation, dierent E. coli strains (DH5a, BL21, INVaF', TOPP1-TOPP3) were tested to optimise protein integrity. Puri®cation with Glutathione-Sepharose beads was according to standard protocols. After elution and threefold dialysis against 1000 volumes of 5 mM TrisHCl pH 7.5, purity and integrity of the fusion proteins were analysed by SDS ± PAGE.
Peptide competition assay
The peptide competition assays in Figure 1 were performed by precipitating c-Crk from c-Crk-virus-infected chicken embryo ®broblast (CEF) lysates as previously described in detail . Precipitated proteins were separated by SDS ± PAGE, blotted and probed with a polyclonal Crk antiserum generated by immunising rabbits with GST-CrkSH3(2).
Peptide anity measurements
Dissociation constants of peptide-SH3 complexes were determined by tryptophan¯uorescence measurements as described previously Cowburn et al., 1995) . Brie¯y,¯uorescence was induced at 290 nm (slid width 2 nm) and measured at an emission wavelength of 345 nm (slid width 17 nm). The peptides were prepared as 5 mg/ml stock solutions, unless indicated otherwise. Peptides with a K d better than 1 mM were measured in a threefold increased sample volume (3 ml). Temperature equilibration of the sample solution was 20 ± 25 min for these samples. The binding constants were calculated using the Origin 4.0 program (Microcal Inc., Northampton, MA) .
Far Western blots and in solution binding assays with biotinylated peptides
Far Western blots were carried out with a 35 S-radiolabelled and puri®ed GST-HACBP-1(AL) probe at a concentration of 0.5 ± 1.0 mg/ml as previously described (Feller et al., 1995a) . In solution binding studies were performed with biotinylated peptides immobilised on Streptavidin-agarose beads (Sigma). 1.2 nMol of peptide (approx. 2 mg) was incubated with 20 ml beads at 48C for 6 ± 16 h in 1 ml of binding buer containing 50 mM TrisHCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.02% sodium azide, 1 mM DTT, 0.01% Tween 20 and 1%(w/v) BSA or Ovalbumin, depending on the M r of the tested fusion proteins. To further reduce nonspeci®c protein-peptide binding, 100 mg of SDS-boiled, 10 000 g-cleared and extensively dialysed total E. coli protein extract was also added to each sample. After three washes with 1 ml of PBS with 0.1% Tween 20 for removal of unbound peptide, 0.5 nMol of anity puri®ed GST-fusion protein (approximately 15 ± 30 mg) were incubated overnight with the immobilised peptide in E. coli protein-supplemented binding buer at 48C on a nutator. Peptide-SH3 complexes were then washed three times as before, separated by 12% SDS ± PAGE and stained with Coomassie-Blue. 5 mg of the tested GST-SH3 fusion proteins were loaded next to the precipitated samples as standards.
Cell culture, metabolic labelling, precipitations and Western blots HeLaS3 cells (obtained from James E Darnell, Rockefeller University, New York, NY) were cultured in DMEM with 5% calf serum and ABAM (Gibco). PC12 rat phaeochromocytoma cells (PC12) were obtained from Moses Chao (Cornell Medical School, New York, NY) and grown in DMEM supplemented with 6% FBS, 3% horse serum and Penicillin/Streptomycin. The human myeloid leukaemia cell line K562 (ATCC) was grown in RPMI supplemented with 5% FBS, 5% calf serum and antibiotics. Cells were harvested and lysed in the presence of protease and phosphatase inhibitors, as described (Feller et al., 1995b) . Metabolic labelling of K562 cells was done according to Green et al. (1985) . 2610 7 cells/ml were labelled with 0.2 mCi per ml 35 S-methionine and 35 S-cystein (Pro-Mix L-[ 35 S] in vitro Cell labelling Mix, Amersham) for 7 h after two 30 min incubations in Met/Cys-free RPMI1640 with 5% dialysed FBS and 5% dialysed calf serum. The cells were then washed with PBS containing 1 mM EDTA and lysed as before. Precipitations were carried out overnight in 20 mM TrisHCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.1% Tween 20, 5% glycerol and protease inhibitors at 48C. To saturate nonspeci®c binding, 2 mg of unlabelled total E. coli protein extract, prepared as described above, was added. 4 mg of total cellular protein extract was used per precipitation with 20 mg of immobilised GST-HACBP-1(AL). Precipitates were washed three times with 1% Triton X-100, 20 mM TrisHCl pH 7.5, 100 mM NaCl, 1 mM EDTA and separated by SDS ± PAGE. Gels were ®xed and treated with Amplify (Amersham) according to the manufacturer's instructions, dried and autoradiographed.
To measure disruption of preexisting complexes between the CrkSH3(1) domain and its binding proteins precipitated from cells, 5 ± 10 mg of total cell lysates were precleared with Glutathione-Sepharose for 2 ± 3 h and precipitated by 10 ± 20 mg immobilized GST-c-CrkSH3(1). After washing with RIPA 500, HACBP was added at 0.1 to 1 mM and incubated again overnight. The ®nal precipitates were washed with RIPA 500, separated by 8% SDS ± PAGE, blotted and renatured (Feller et al., 1995a) . Bound 35 S-radiolabelled GST-c-CrkSH3(1) (probe concentration 20 mg/ml) was detected with a phosphoimager (Fuji BAS Reader) and subsequently by autoradiography.
For CRKL-Western Blots, a commercial antiserum (sc-319; Santa Cruz) was used. c-Crk was detected with a commercial monoclonal antibody (Transduction Laboratories). Secondary antibodies used for CRKL-and Crk-immunoblots were F(ab) 2 -anti rabbit peroxidase and F(ab) 2 -anti mouse peroxidase conjugates, respectively (Jackson ImmunoResearch Laboratories). ECL reagents were from Amersham.
